chevron_leftBack
As of 15 June 2026, CytoDyn Inc. has a market cap of $419.67M USD, ranking #16337 globally and #2762 in the United States.
It ranks #1472 in the Healthcare sector, and #533 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$419.67MUSD
Enterprise Value
$432.84MUSD
EBITDA (TTM)
-$21.4MUSD
Net Income (TTM)
-$40.28MUSD
PB Ratio
-4.0
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Jacob Lalezari
open_in_new
Employees
13
Founded
2002
Website
cytodyn.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0.3% | -15% | 21% | 31% | 28% | 36% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
CYDY
CytoDyn Inc
ISIN: US23283M1018
Shares Out.:
Shares Outstanding:
1.366B1
Shares Float:
1.366B2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.3100 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About CytoDyn Inc.
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company’s leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. It has a collaboration with Creatv Bio. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
181K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
130K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
86K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
65K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
35K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
28K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$320.51B
76K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.14B
69K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$273.78B
65K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.97B
43K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.21B
26K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.2B
26K%
80.96B GBP
|
14.6
|
chevron_leftBack